BIIB Biogen
- 202.400
- -1.670-0.82%
Biogen News
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
Investors Can Find Comfort In Biogen's (NASDAQ:BIIB) Earnings Quality
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $251
Mizuho Maintains Outperform on Biogen, Lowers Price Target to $251
Express News | Biogen : Canaccord Genuity Cuts Target Price to $298 From $308
Express News | Biogen : Mizuho Cuts Target Price to $251 From $277
Results: Biogen Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Express News | Biogen Shares Are Trading Lower After Needham and Truist Securities Lowered Their Respective Price Targets on the Stock
Mizuho Adjusts Biogen's Price Target to $251 From $277, Keeps Outperform Rating
Biogen Price Target Cut to $302.00/Share From $340.00 by Truist Securities
Truist Financial Maintains Biogen(BIIB.US) With Buy Rating, Announces Target Price $302
Express News | Biogen : Truist Securities Cuts Target Price to $302 From $340
Express News | Biogen : Guggenheim Cuts Target Price to $245 From $255
Express News | Needham Maintains Buy on Biogen, Lowers Price Target to $285
Buy Rating Affirmed for Biogen Amid Strong Core Performance and Strategic Growth Initiatives
Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $250
Oppenheimer Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $270
Biogen Price Target Cut to $225.00/Share From $240.00 by Wells Fargo
Express News | Scotiabank Maintains Sector Outperform on Biogen, Lowers Price Target to $244
Analysis
Price Target
No Data
